334 related articles for article (PubMed ID: 12659981)
1. Early remodelling of left ventricle and improvement of myocardial performance in patients after percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy.
Veselka J; Honek T
Int J Cardiol; 2003 Mar; 88(1):27-32. PubMed ID: 12659981
[TBL] [Abstract][Full Text] [Related]
2. Effects of alcohol septal ablation for hypertrophic obstructive cardiomyopathy on Doppler Tei index: a midterm follow-up.
Veselka J; Procházková S; Bolomová-Homolová I; Duchonová R; Tesar D
Echocardiography; 2005 Feb; 22(2):105-9. PubMed ID: 15693775
[TBL] [Abstract][Full Text] [Related]
3. The biphasic course of changes of left ventricular outflow gradient after alcohol septal ablation for hypertrophic obstructive cardiomyopathy.
Veselka J; Duchonová R; Procházková S; Homolová I; Pálenícková J; Zemánek D; Pernisová Z; Tesar D
Kardiol Pol; 2004 Feb; 60(2):133-6; discussion 137. PubMed ID: 15116158
[TBL] [Abstract][Full Text] [Related]
4. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery.
Qin JX; Shiota T; Lever HM; Kapadia SR; Sitges M; Rubin DN; Bauer F; Greenberg NL; Agler DA; Drinko JK; Martin M; Tuzcu EM; Smedira NG; Lytle B; Thomas JD
J Am Coll Cardiol; 2001 Dec; 38(7):1994-2000. PubMed ID: 11738306
[TBL] [Abstract][Full Text] [Related]
5. [Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results in 66 patients with reference to myocardial contrast echocardiography].
Faber L; Seggewiss H; Fassbender D; Bogunovic N; Strick S; Schmidt HK; Gleichmann U
Z Kardiol; 1998 Mar; 87(3):191-201. PubMed ID: 9586154
[TBL] [Abstract][Full Text] [Related]
6. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Acute results and three-year noninvasive follow-up in 18 patients.
Guo H; Wang J; Chen J; Shan J; Lee JD; Ueda T
Can J Cardiol; 2004 Jun; 20(8):779-82. PubMed ID: 15229758
[TBL] [Abstract][Full Text] [Related]
7. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients.
Seggewiss H; Gleichmann U; Faber L; Fassbender D; Schmidt HK; Strick S
J Am Coll Cardiol; 1998 Feb; 31(2):252-8. PubMed ID: 9462563
[TBL] [Abstract][Full Text] [Related]
8. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy; The Chinese experience in 119 patients from a single center.
Li ZQ; Cheng TO; Zhang WW; Qiao SB; Zhao LY; Jin YZ; Guan RM; Liu L
Int J Cardiol; 2004 Feb; 93(2-3):197-202. PubMed ID: 14975547
[TBL] [Abstract][Full Text] [Related]
9. [Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy].
Qiao SB; Gao RL; You SJ; Yuan JS; Chen JL; Yang YJ
Zhonghua Nei Ke Za Zhi; 2006 Mar; 45(3):210-2. PubMed ID: 16624154
[TBL] [Abstract][Full Text] [Related]
10. [Percutaneous transluminal septal myocardial ablation: early results and long-term follow-up].
Tekieli Ł; Pieniazek P; Podolec P; Tomkiewicz-Pajak L; Płazak W; Musiałek P; Leśniak-Sobelga A; Przewłocki T; Biernacka B; Zmudka K; Tracz W
Przegl Lek; 2006; 63(8):628-32. PubMed ID: 17441371
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up after percutaneous septal ablation in hypertrophic obstructive cardiomyopathy.
Seggewiss H; Rigopoulos A; Welge D; Ziemssen P; Faber L
Clin Res Cardiol; 2007 Dec; 96(12):856-63. PubMed ID: 17891517
[TBL] [Abstract][Full Text] [Related]
12. Non-surgical myocardial reduction in hypertrophic obstructive cardiomyopathy.
Mutlak D; Gruberg L; Reisner S; Markiewicz W
Isr Med Assoc J; 2002 Feb; 4(2):86-90. PubMed ID: 11875998
[TBL] [Abstract][Full Text] [Related]
13. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy through non-left anterior descending septal perforators.
Imori Y; Takano H; Kitamura M; Aoyama R; Sangen H; Kenta O; Matsuda J; Kubota Y; Tokita Y; Yamamoto T; Asai K; Takayama M; Shimizu W
Heart Vessels; 2020 May; 35(5):647-654. PubMed ID: 31641886
[TBL] [Abstract][Full Text] [Related]
14. Comparison of percutaneous transluminal septal myocardial ablation versus septal myectomy for the treatment of patients with hypertrophic obstructive cardiomyopathy--a meta analysis.
Zeng Z; Wang F; Dou X; Zhang S; Pu J
Int J Cardiol; 2006 Sep; 112(1):80-4. PubMed ID: 16507323
[TBL] [Abstract][Full Text] [Related]
15. Percutaneous transluminal septal myocardial ablation in drug-resistant hypertrophic obstructive cardiomyopathy: 18-month follow-up results.
Oomman A; Ramachandran P; Subramanyan K; Kalarickal MS; Osman MN
J Invasive Cardiol; 2001 Jul; 13(7):526-30. PubMed ID: 11435640
[TBL] [Abstract][Full Text] [Related]
16. Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: A 16-Year Australian Single Centre Experience.
Nogic J; Koh Y; Bak M; Gooley RP; Meredith IT; McCormick LM
Heart Lung Circ; 2018 Dec; 27(12):1446-1453. PubMed ID: 29129561
[TBL] [Abstract][Full Text] [Related]
17. Long term exercise capacity in patients with hypertrophic cardiomyopathy treated with percutaneous transluminal septal myocardial ablation.
Malek LA; Chojnowska L; Klopotowski M; Maczynska R; Demkow M; Witkowski A; Kusmierczyk B; Piotrowicz E; Konka M; Dabrowski M; Ruzyllo W
Eur J Heart Fail; 2008 Nov; 10(11):1123-6. PubMed ID: 18840395
[TBL] [Abstract][Full Text] [Related]
18. [Non-pharmacologic therapy of hypertrophic obstructive cardiomyopathy--results of therapy based on percutaneous transluminal septal myocardial ablation compared with results of dual-chamber cardiac pacing].
Krejcí J; Groch L; Meluzín J; Vykypel T; Halámek J; Vitovec J
Vnitr Lek; 2006 Apr; 52(4):313-20. PubMed ID: 16755987
[TBL] [Abstract][Full Text] [Related]
19. Percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy.
Seggewiss H; Faber L; Gleichmann U
Thorac Cardiovasc Surg; 1999 Apr; 47(2):94-100. PubMed ID: 10363608
[TBL] [Abstract][Full Text] [Related]
20. Reverse remodeling after percutaneous transluminal septal myocardial ablation in severe but asymptomatic LVOT obstruction (RASTA) study: Rationale and design of transcatheter septal reduction in asymptomatic patients with severe hypertrophic obstructive cardiomyopathy.
Arslan F; Akdim F; Ten Berg JM
Catheter Cardiovasc Interv; 2021 Feb; 97(3):488-492. PubMed ID: 32808736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
